Author Archives: admin


International Stem Cell Corp Announces Third Quarter 2012 Financial Results

CARLSBAD, CA--(Marketwire - Nov 9, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company focused on therapeutic and research products, today announced financial results for the three months ended September 30, 2012.

Three Months Ended September 30, 2012

Revenue for the three months ended September 30, 2012 totaled $1.19 million compared to $0.84 million for the same period in 2011.Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 46% and 37%, respectively. LSC and LCT accounted for 44% and 56% of total revenue in the three months ended September 30, 2012 compared to 43% and 57%, respectively, for the same period of 2011.

Research and development (R&D) expenses were $0.90 million for the three months ended September 30, 2012, compared to $1.13 million for the same period in 2011. The decrease was due primarily to lower stock-based compensation expense, lower personnel-related spending and lower consulting expenses, partially offset by higher stem cell line research and testing expenses and higher laboratory expenses associated with our Parkinson's disease program.

The Company continues to invest in its sales and marketing infrastructure. Marketing expenses for the three months ended September 30, 2012 were $0.48 million, compared to $0.37 million for the same period in 2011. The increase was primarily driven by investments to promote and build awareness of the Lifeline Skin Care brand and branded products. General and administrative expenses were $1.57 million, down 26% compared to the same period in 2011, as a result of ongoing operational efficiency initiatives.

Cash and cash equivalents totaled $2.38 million at September 30, 2012 compared to $1.34 million as of December 31, 2011 due primarily to two financing transactions totaling approximately $7.03 million completed in the first three months of 2012.

"We have made excellent progress in our therapeutic development programs, being able to start our non-human primate study in our Parkinson's disease program earlier than anticipated, and we remain on track to publish the results in the first half of next year," stated Dr. Andrey Semechkin, ISCO's CEO and Co-Chairman. "In addition, our results for the third quarter reflect good progress by LSC and LCT both in terms of growing sales and implementing their strategies. Particularly pleasing is LSC's continued revenue growth as they aim to diversify their sales channels, and LCT's strong quarter on quarter performance. General and administrative expenses continued to decrease reflecting our increased focus on cost containment.Looking ahead to next year, we anticipate our R&D expenses to increase further as we expand our pharmacology and safety studies and our Parkinson's program moves closer to IND filing in early 2014."

Q3 2012 Highlights:

Conference Call and Webcast Details:

Date: Friday, November 9, 2012 Time: 11:00 a.m. Eastern Time

Visit link:
International Stem Cell Corp Announces Third Quarter 2012 Financial Results

Govt. Appoints Task Force To Explore Stem Cell Research – Video


Govt. Appoints Task Force To Explore Stem Cell Research
Minister of Health Hon. Dr. Perry Gomez announced that the government has appointed a 10 member task force, charged with making recommendations to the government to explore stem cell therapy in The Bahamas.From:ZNSNetworkViews:5 0ratingsTime:03:27More inNews Politics

See original here:
Govt. Appoints Task Force To Explore Stem Cell Research - Video

123Triad : wwmsbiologicscom – Video


123Triad : wwmsbiologicscom
123Triad is proud to design website for http://www.wwmsbiologics.com WorldWide Medical Services Inc. is a company that for more than 10 years is dedicated to utilizing the most innovative technologies to provide its clients with the highest quality services. Worldwide Medical Services specializes in the Intra-operative treatment of surgical patients. One of their most exciting new products is platelet gel and adult stem cell therapy services which can be provided in a hospital or office setting. their Autotransfusion service is available 24/7 on a scheduled or emergency basis.From:123triadcoViews:0 0ratingsTime:00:36More inScience Technology

See the original post:
123Triad : wwmsbiologicscom - Video

CombiCult® Workflow – Video


CombiCult Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:0 0ratingsTime:06:40More inScience Technology

View original post here:
CombiCult® Workflow - Video

UPDATE on Stem Cell Therapy 7 November 2012

UPDATE on Stem Cell Therapy

7 November 2012

The Department of Health (DOH) saw the necessity to cover regulations for Stem Cell therapy. Stem Cell therapy belongs to the category of Advanced Cell therapy which includes biologics and blood. Many countries around the world apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy. In many countries, Stem Cell is considered an investigational intervention.

Stem Cell research employs both autologous (from same person) or allogenic (from another organism like animal or another human cell or tissue sample) method. Because there are many steps in the preparation of this lab and invasive procedure, there is therefore need to have a regulatory framework to protect Filipino citizens.

Important questions were asked: is there proof of concept in animal trials where stem cell can then be applied in humans? Is there a way to ensure quality and purity of the raw materials? How safe is the procedure? How many did not benefit from the procedure? If this were investigational procedure, how will human subjects be protected?

Sec. Enrique Ona convened a consultative working task force to provide recommendations on how to proceed in the early part of the year in response to queries and mushrooming of centers here and overseas. This led to the creation of a regulatory task force to oversee the appropriate steps that will ensure quality, efficacy and safety documentation of this intervention.

Read the original post:
UPDATE on Stem Cell Therapy 7 November 2012

Stem-cell research facility planned

American cardiologist and researcher Dr. Yerem Yeghiazarians is currently on a visit to the Kingdom to gauge interest in setting up a stem-cell research facility here.

Leading Saudi businessmen Hamad and Khalid Al-Zamil are interested in advancing the research initiative and invited Dr. Yeghiazarians to meet business leaders, arranged lectures and toured him around various hospitals to garner support for his pioneering project.

Dr. Yeghiazarians believes stem cell treatment may be the only hope for thousands of people worldwide who suffer from heart problems.

"It would be fantastic if we could set up a research program here. I am trying to monitor the interest among people here. I need to know what facilities are currently available and find out how we can introduce larger facilities to the region to advance the research collaboratively," he told Arab News in an interview.

"My mission is to educate people here about stem cell research, heart diseases, heart failure and the potential treatment we can offer our patients," said Dr. Yeghiazarians.

In the US alone, he pointed out that there are about 1.5 million heart attacks every year, and one in five people are going to die from heart disease. There are over three million people in the US with some degree of congestive heart failure now.

"In the Middle East, I dont know the numbers, but they must be equally staggering," he said.

"We all have to be careful about our diet. We all have to be careful about the lifestyle choices we make. We should not smoke; we should exercise and constantly watch our weight."

Please read full story on Page 4

Here is the original post:
Stem-cell research facility planned

Some critics impatient over slow stem-cell research payoff

California's historic Proposition 71 provided big money for stem-cell research after voters approved it eight years ago. The measure helped fund major advances, but some charge that the success has been hampered by cronyism and conflict of interest.

Roman Reed has been a paraplegic for more than eighteen years. Ever since a college football injury injured his spine. Reed says he's confident he will walk again.

"Stem cells are going to get me out of this chair. I will walk again one day because of stem cell research," said Reed.

He campaigned hard for Prop 71 eight years ago. Voters believed stem cells might help find cures for paralysis, heart disease, diabetes and more.

The proposition won and the California Institute for Regenerative Medicine or CIRM received $3 billion from taxpayers. The bond money was intended to find stem cell cures.

Some are starting to question whether they have found any.

"We do not have any cures, nor did we expect to have any cures within the time frame that we've funded so far," said CIRM's Chairman Jonathon Thomas.

They have spent $1.7 billion dollars to date. The money has been used to build a dozen new laboratories. It has also funded 1200 papers on 38 incurable diseases and lured 150 top scientists to California.

CIRM is backing seven clinical trials, but the FDA has not approved even one stem-cell therapy procedure. Six months ago, U.S. doctors got the green light to use a Canadian treatment for dying children.

Director of Stem Cell Program at UC Davis Institute for Regenerative Cures Jan Nolta believes it is a great advancement in medicine.

Original post:
Some critics impatient over slow stem-cell research payoff

Stem cell research facility considered for Saudi Arabia

(MENAFN - Arab News) American cardiologist and researcher Dr. Yerem Yeghiazarians is currently on a visit to the Kingdom to gauge interest in the establishment of a stem-cell research facility here.

Leading Saudi businessmen Hamad and Khalid Al-Zamil are interested in advancing the research initiative and invited Yeghiazarians to meet business leaders, arranged lectures and toured him around various hospitals to garner support for his pioneering project.

Dr. Yeghiazarians believes stem cell treatment may be the only hope for thousands of people worldwide who suffer from heart problems. Dr. Yeghiazarians speaks to Arab News journalist Siraj Wahab on the latest developments in the field.

Dr. Yeghiazarians, welcome to Saudi Arabia. Is this your first visit? Please tell us more about yourself and your medical background. Yes, this is my first time in Saudi Arabia. It is truly an honor being in the Kingdom. I am a cardiologist. I also do interventional cardiology, meaning I do procedures in patients who have blockages in their arteries or who have heart attacks. I did my training mostly in the United States. My medical school training was at Johns Hopkins Medical School in Maryland. After that I spent eight years at Harvard Medical School at the Brigham and Women's Hospital, one of their main teaching hospitals. It is one of the most respected training institutions in the country, if not the best. I finished my internal medicine training there and decided to do cardiology training. When I completed my clinical training in cardiology, I was asked to go back and take a chief residency for the whole Brigham and Women's Hospital internal medicine residency program. I was the chief resident in charge of training 170 trainees in internal medicine that year. I finished my training for interventional cardiology and did my research at Harvard and in 2003 was recruited to the University of California, which is a world-renowned medical and research institution. I was doing interventional cardiology and started a cardiac stem cell program.

What was the level of interest in 2003 to stem cell research and what exactly is it? Back in 2003, it was a very new research endeavor. The basic idea of our research is to use stem cells to improve heart function after a heart attack. What tends to happen to patients who suffer from a heart attack is because of the lack of blood flow and the blockage that develops in the heart artery, the heart muscle becomes damaged and scarred. The heart, unlike the other organs in the body, doesn't have enough capacity to regenerate itself. Once you have a heart attack that muscle is damaged. It is replaced by scar tissue. Over time the heart loses its pumping capacity and is unable to pump blood out of the heart to rest of the body. It is like pouring water into a balloon. The balloon gets bigger and loses its pumping capacity. Blood or fluid builds up in the lungs and leads to congestive heart failure or cardiomyopathy. It is the number one killer in the developed world and results from risk factors such as diabetes, smoking or high blood pressure.

How do you treat congestive heart failure? Over the last 20 to 30 years, a lot of effort has been made to develop medications to improve heart function after a heart attack. None of the therapy we have is adequate to help all our patients. Some make progress but they need mechanical devices like heart pumps. Sometimes even that fails. The only way is to do a heart transplant. But even in the United States we do less than 3,000 heart transplants a year. Thousands of patients need advanced therapy. Unfortunately, none of the drugs today can replace heart scar tissue with a beating, functional muscle cell. The only hope we have is to use stem cells to regenerate the scar tissue and replace it with a heart muscle cell and improve heart function. This will eliminate the need for mechanical intervention or a heart transplant. Heart transplants are very rare and in many parts of the world it is impossible for patients to have them.

How far are we into stem cell research? There are different types of stem cells we can use for treating ailments. There are adult stem cells and there are embryonic stem cells. There is a new development called induced pluripotent stem cells, otherwise known as IPS cells. This was an amazing discovery. Last month the Nobel Prize in Medicine went to the two people who discovered it. The scientists took a skin cell and genetically manipulated it and make this cell into a stem cell or a younger cell. We all come from a young cell. This discovery meant we can turn the clock back to an immature cell from which different types of cells can be created, enabling us to treat all conditions in the future. It is still early days but there is a lot of promise. We have come a long way using adult stem cells in ongoing clinical trials, which appear to show a lot of promise. In the future the hope is to use these cells to replace the scar tissue with a viable heart muscle cell.

Do you intend to establish a research facility in Saudi Arabia? From my understanding there is not much research going on in this field here or in the region. So it is an honor for me to come here and introduce the research we are doing at the University of California and to extend our knowledge to the folks here in the Middle East and Saudi Arabia specifically. The idea is to garner interest and to see if people are interested in collaborating with us in starting a similar project here. We are very hopeful that in the future we can collaborate to advance the research we have for the treatment of heart patients.

What kind of laboratory do you have in California? We do basic research that involves growing cells at my laboratory. We also have small-animal models and large-animal models whereby we can study them before we introduce them to patients. It would be fantastic if we could set up a similar research program here. I am trying to monitor the interest among people here. I need to know what facilities are currently available and find out how we can introduce larger facilities to the region advance the research collaboratively.

What is the cost to set up a similar one here? It is hard to put a figure on it. It depends on how big a program people here would be interested in. We are talking about millions of dollars. I will give you an example. At the University of California about two or three years ago, we created a whole new building specifically to study stem cells and that cost about 200 million. We have more than 20 investigators who study stem cells for different disease conditions, not just the heart but for other conditions too. Stem cells could some day potentially be used for patients following a stroke and for patients with diabetes, kidney disease and liver failure. There are endless possibilities." This is the time to invest in it, to put a program together, because it is not that we are going to discover it over the next year or two. This is going to help our future generation, our medical students, create novel treatment for all kinds of diseases.

Original post:
Stem cell research facility considered for Saudi Arabia

Promising Stem Cell Research Driving Industry's Growth in 2012

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) and Neostem Inc. ( NYSE : NBS ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/ASTM

http://www.FiveStarEquities.com/NBS

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is a leader in the development of patient-specific multicellular therapies for the treatment of severe, chronic cardiovascular diseases. Stem cell therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition.

NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

More:
Promising Stem Cell Research Driving Industry's Growth in 2012